Lauren Bowen Reoma, M.D.

Headshot of Lauren Bowen Reoma
Staff Clinician, Deputy Clinical Director, and Director, Clinical Trials Unit, Office of the Clinical Director
Clinical Trials Unit (CTU)

BG 10 RM 2A23

Dr. Lauren B. Reoma is a Staff Clinician who supports the intramural NINDS program as Deputy Clinical Director and Director of the NINDS Clinical Trials Unit. She is a board-certified neurologist who received her medical degree from and completed her neurology residency at the University of Florida College of Medicine. At NIH, she trained as a Clinical Fellow in the NINDS Neuroimmunology and Neurovirology Program where she completed additional training in Clinical Trials Methodology, Clinical Investigator Training, as well as rotated briefly through the Division of Neurology Products, CDER, FDA. She is the intramural fellowship director for the NINDS-FDA Division of Neurology Clinical Trials Methodology and Regulatory Science Fellowship in conjunction with CDER/FDA and extramural NINDS. Within NIH, she is a member of the NIH Institutional Review Board, the NIH Biosafety Committee, the NIH Sterile Products for Human Administration Committee and oversees the NINDS central Data and Safety Monitoring Board. Dr. Reoma is the Sponsor’s Authorized Representative for intramural NINDS. She is a member of multiple outside academic committees, including as a member of the ACTG Neurology CSG, the Vice Chair of the AAN’s Experimental Neurotherapeutics Section and a member of the program committee of ASENT. Her research focuses on understanding the CNS viral reservoir as well as on developing practices for gold-standard early-phase clinical trials methodology and regulatory science in neurologic disease.

Dr. Reoma’s primary research interest has been working to identify and target CNS viral reservoirs, especially as pertains JCV and HIV-1. She is the Principal Investigator on clinical study NCT03239899: PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection under IND, which is a phase 1 study using checkpoint inhibition to target a “kick-and-kill” mechanism intended to reverse viral latency in HIV-1 for potential use in cure designs. This study will shed important light on questions of CD4 killing, CD4 clonality, HIV-1 viral insertion, HIV antibody response (9), tat antigen response, and cytokine response in the peripheral and CNS space. In tandem, her work on CNS viral reservoirs (Dengue, JCV, HIV-1) has supported research and studies instrumental in identifying and understanding CNS viral reactivations as well as potential therapeutic targets.

In parallel to her work in neurovirology, she is leading development of a research program within the Clinical Trials Unit focused on optimizing novel clinical trials methodology, improving trial regulatory performance, and targeting quality improvement research in early phase neurology clinical trials. The unit has published work focusing on mitigating non-compliance in neurology clinical trials and has presented at several local, national, and international conferences. Growth in this program is targeting work on novel and optimal designs in low “n” rare disease populations, quality assurance event mitigation in early phase designs, development of standardized neurology clinical trials database management systems, development of a toxicology criteria for clinical neurologic researchers, and metrics for gold-standard early phase interventional trial support staffing in neurologic trials.

Cortese I, Beck ES, Al-Louzi O, Ohayon J, Andrada F, Osuorah I, Dwyer J, Billioux BJ, Dargahzada N, Schindler MK, Binder K, Reoma L, Norato G, Enose-Akahata Y, Smith B, Chiara Monaco M, Major EO, Jacobson S, Stroncek D, Highfill S, Panch S, Reich DS, Barrett J, Nath A, Muranski P. Pilot study of virus-specific T cells for immunotherapy of PML. Lancet Neurology. August 2021. Lancet Neurol. 2021 Aug;20(8):639-652. doi: 10.1016/S1474-4422(21)00174-5.PMID: 34302788

Gooden MJ, Norato G, Martin SB, Reoma LB. Reducing Events of Noncompliance in Neurology Human Subjects Research: the Effect of Human Subjects Research Protection Training and Site Initiation Visits. Neurotherapeutics. Neurotherapeutics. 2021 Apr;18(2):859-865. doi: 10.1007/s13311-020-01003-4. Epub 2021 Jan 21.PMID: 33475954

Bharucha T, OeserC, BallouxF, BrownJR, CarboE, CharlettA, ChiuC, ClaasECJ, de GoffauM, de VriesJ, EloitM, HopkinsS, HuggettJF, MacCannellD, MorfopoulouS, NathA, O’SullivanDM, ReomaLB, ShawLP, SidorovI, SimnerPJ, TanLV, ThomsonEC, van DorpL, WilsonMR, BreuerJ, Field N. STROBE-Metagenomics: A STROBE/STROME-ID Extension Statement to Guide the Reporting of Studies Applying Metagenomics. Lancet Infect Dis. 2020 Oct;20(10):e251-e260. doi: 10.1016/S1473-3099(20)30199-7. Epub 2020 Aug 5.

Gugger JJ*, Reoma LB*, Olson V, Soni M, Tiryaki E, Noble JM on behalf of the AAN Undergraduate Education Subcommittee. A Practical Guide for Medical Students who are Planning a Future in Neurology. Neurology. Neurology. 2020 Apr 14;94(15):673-677. doi: 10.1212/WNL.0000000000009247. Epub 2020 Mar 12.PMID: 32165447

HendersonL*, ReomaLB*, Kovacs L, NathA. Advances towards curing HIV-1 infection from tissue reservoirs. JVI. J Virol. 2019 Nov 6. pii: JVI.00375-19. doi: 10.1128/JVI.00375-19. [Epub ahead of print] Review.

Cordes LM, Davarpanah NN, Reoma LB, Gasmi B, Quezado M, Khan OI, Nath A, Apolo AB. Neurotoxicities associated with checkpoint inhibitors: two case reports and a review of the literature. Clinical Case Reports. Accepted September 2019.

Reoma LB, Trindade C, Monaco-Kushner M, SolisJ, Montojo MG, Vu P, Beck E, Khan O, Quezado M, Reich DS, Childs R, Nath A. Fatal Encephalopathy within the context of Wild-type JC Virus and Ruxolitinib Therapy. Ann Neurol. 2019 Dec;86(6):878-884. doi: 10.1002/ana.25608. Epub 2019 Oct 16.

Johnson TP, Larman HB, Lee MH, Whitehead SS, Kowalak J, Toro C, Lau C, Kim J, Johnson K, Reoma LB, Faustin A, Pardo C, Kottapalli S, Howard J, Monaco D, Weisfeld-Adams J, Blackstone C, Galetta S, Snuderl M, Gahl WA, Kister I, Nath A. Chronic Dengue Encephalitis in a Patient with Progressive Dementia and Extrapyramidal Features. Ann Neurol. 2019 Nov;86(5):695-703. doi: 10.1002/ana.25588. Epub 2019 Sep 11.

Henderson LJ, Johnson TP, Smith B, Reoma LB, Santamaria UA, Bachani M, Demarino C, Barclay RA, Snow J, Sacktor N, Mcarthur J, Letendre S, Steiner J, Kashanchi F, Nath A. Presence of Tat and Trans-activation response (TAR) element in spinal fluid despite antiretroviral therapy. AIDS.2019 Dec 1;33 Suppl 2:S145-S157. doi: 10.1097/QAD.0000000000002268.

Cortese I, Muranski P, Akahata Y, Ha SK, Smith B, Monaco MC, Ryschewitsch C, Major EO, Ohayon J, Schindler M, Beck E, Reoma LB, Jacobson S, Reich DS, Nath A. Treatment of progressive multifocal leukoencephalopathy with a checkpoint-inhibitor. NEJM. 2019 Apr 10; doi: 10.1056/NEJMoa1815039.

Bowen LN, Smith B, Reich D, Quezado M, Nath A. Opportunistic CNS Infections in HIV-infected individuals. Nat Rev Neurol. 2016 Oct 27;12(11):662-674.

Margaret Gatti-Mays MD MPH, Maura Manion MD, Lauren Bowen MD, G. Thomas Brown, MD PhD, Robert Danner MD, Omar Khan MD, Avindra Nath MD, Minoo Battiwalla MD, Austin John Barrett MD, Sawa Ito MD. Toxoplasmosis Encephalitis with Immune-Reconstitution Inflammatory Syndrome in an allogeneic stem cell transplant patient. Bone Marrow Transplant. 2016 Dec;51(12):1622-1624.

Bowen LN, Tyagi R, Li W, Alfahad T, Smith B, Wright M, Singer E, Nath A. HIV-associated Motor Neuron Disease: HERV-K Activation and response to anti-retroviral therapy. Neurology 2016;87:1–7.

Bowen LN, Moore DF, Okun MS. Is Blast Injury a Modern Phenomenon? Early Historical Descriptions of Mining and Volcanic Traumatic Brain Injury with relevance to Modern Terrorist Attacks and Military Warfare. Neurologist. 2016 Mar;21(2):19-22.

Bowen LN, S.H. Subramony MD, Kenneth M. Heilman MD. Apraxia in Anti-GAD Associated Stiff Person Syndrome: Link to Corticobasal Degeneration? Ann Neurol. 2015 Jan;77(1):173-6

Michael S. Okun, MD,Samuel S. Wu, PhD, Sarah Fayad, M.D., Herbert Ward, M.D., Dawn Bowers, PhD., Christian Rosado, MD, Lauren Bowen, MD, Charles Jacobson, BS, Christopher Butson, PhD., Kelly Foote, MD. Acute and Chronic Mood and Apathy Outcomes from a randomized study of unilateral STN and GPi DBS. PLos One. 2014 Dec 3;9(12):e114140.                       

Bowen LN, Malaty IA, Rodriguez RL, Okun MS. Did General Douglas MacArthur have Parkinson’s Disease? A video and archival analysis. Neurology. 2011 May 10;76(19):1668-72.

Bowen LN, Subramony SH, Cheng J, Wu SS, Okun MS. Elementary My Dear Dr. Allen: The Case Of Barium And Pa Ping. Neurology. 2010 May 11;74(19):1546-9